Today's Technical View: Elan Corp., Amarin, Seattle Genetics, and Cubist Pharma Editor Note: For more information about this release, please scroll to bottom.

LONDON, July 5, 2013 /PRNewswire/ --

On Wednesday, July 3, 2013, shares in biotechnology companies and drug manufacturers ended mostly lower even as the broader market posted modest gains. The major movers in the sector included Elan Corporation Plc (ADR) (NYSE: ELN), Amarin Corporation Plc (ADR) (NASDAQ: AMRN), Seattle Genetics Inc. (NASDAQ: SGEN), and Cubist Pharmaceuticals Inc. (NASDAQ: CBST). All these companies are tracked by AAAResearchReports.com. Free in-depth technical analysis on ELN, AMRN, SGEN, and CBST are currently available upon sign up at:

http://www.aaaresearchreports.com/register/  

Shares in Elan Corporation Plc struggled on Wednesday even as the broader market posted gains. The company's shares oscillated between $14.05 and $14.22 before closing the day 0.70% lower at $14.12. A total of 3.65 million shares were traded which is below the daily average volume of 15.85 million. The company's shares are still trading near their 52-week high of $14.80. In the last three months, the stock has gained 21.62%, thus outperforming the S&P 500 which gained 3.55% in the same period. Sign up for free technical analysis on ELN at:

http://www.AAAResearchReports.com/ELN070513.pdf

Amarin Corporation Plc's stock rose sharply on Wednesday, finishing at $5.83, up 2.10% from its previous closing price. The company's shares oscillated between $5.59 and $5.86. A total of 1.45 million shares were traded which is less than its daily average volume of 3.71 million. Despite Wednesday's rally, the company's shares are still trading near their 52-week low of $5.36. In the last one month, the stock has fallen 15.63%. Download free report on AMRN by registering at:

http://www.AAAResearchReports.com/AMRN070513.pdf

Shares in Seattle Genetics Inc. edged lower on Wednesday, reversing some of their gains for the week. The company's shares ended the day 0.27% lower at $33.52 after fluctuating between $33.31 and $33.97. A total of 536,902 shares were traded which is less than the daily average volume of 1.24 million. The stock has fallen 0.33% in the last one month. The free report on SGEN can be downloaded by signing up now at:

http://www.AAAResearchReports.com/SGEN070513.pdf

Cubist Pharmaceuticals Inc.'s stock ended slightly lower on Wednesday. The stock closed the day at $52.48, down 0.08% from its previous closing price. The company's shares oscillated between $51.87 and $53.17. A total of 745,494 shares were traded which is below the daily average volume of 1.19 million. The company's shares are currently trading near their 52-week high of $56.68. Moreover, the stock is trading above its 50-day and 200-day moving averages. In the last three months, the company's shares have gained 14.11%, thus outperforming the S&P 500. A free report on CBST can be accessed by registering at:

http://www.AAAResearchReports.com/CBST070513.pdf

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


SOURCE AAA Research Reports




Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.